The American Cancer Society says more people will be diagnosed with cancer this year than ever before. Conventional treatments like surgery, chemotherapy, and radiation are helping to prevent deaths, but can more be done? Emerging research focused on repurposed drugs is proving the answer is YES.
The FLCCC Alliance is proud to announce it has partnered with renowned breast cancer physician and researcher Kathleen Ruddy, MD, to conduct an observational study in collaboration with three U.S. clinics to track patient responses to various adjunct cancer therapies using repurposed drugs. The aim is to determine changes in the five-year survival rate of several types of cancer including breast, prostate, lung, and colorectal.
Study Details
Dr. Marik announces the cancer study partnership with Dr. Ruddy at the Winter 2024 FLCCC Educational Conference.
The final study results will focus on changes in the five-year survival rate of certain cancers and include patients from three clinics nationwide that will collaborate and share de-identified patient information in a protected data collection tool where the data will be tracked and analyzed.
Although the study uses the five-year survival rate after diagnosis as an endpoint, periodic updates of preliminary results will be provided while the study progresses. The study IRB has been officially approved by WCG, which places it in full compliance with all federal guidelines.
The FLCCC Alliance published its Cancer Care Monograph in June 2023. In the FLCCC research partnership with Dr. Ruddy, we hope to build on the already promising results she has documented. It is our mission to bring safe, affordable, and effective cancer treatments to the patients who so desperately need them.
How It Will Work
Please Note: While there is no cost to enroll in the study, each patient will be responsible for the medical advice and treatment therapies provided by the participating clinics. Costs vary, since each clinic sets its own pricing – some focus on complementary care and work with the patients’ existing oncologists, while others provide end-to-end cancer care including a combination of traditional cancer treatments as well as complementary care using repurposed drugs. Clinic-based therapies are typically more expensive than telemedicine and costs will vary based on each patient’s medical history.
Study Leaders
Dr. Ruddy and Dr. Marik will act as lead investigators with Dr. Pierre Kory acting as contributing author.
Founder, Health and Healing
Lead Investigator, FLCCC Cancer Study
